Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average) (2010 - 2026)

Whitehawk Therapeutics (WHWK) has 17 years of Shares Outstanding (Weighted Average) data on file, last reported at $69.2 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $69.2 million, up 74.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $69.2 million (up 74.66% YoY), and the FY2025 annual result was $20.1 million, down 25.72% from the prior year.
• Shares Outstanding (Weighted Average) grew to $69.2 million in Q1 2026 per WHWK's latest filing, from $20.1 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $69.2 million in Q1 2026 and troughed at $29166.0 in Q1 2022.
• A 5-year average of $26.3 million and a median of $26.9 million in 2023 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2024: Shares Outstanding (Weighted Average) slumped 99.86% in 2023, then jumped 92454.45% in 2024.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $29167.0 in 2022, then jumped by 92189.12% to $26.9 million in 2023, then increased by 0.42% to $27.0 million in 2024, then slipped by 25.72% to $20.1 million in 2025, then soared by 244.87% to $69.2 million in 2026.
• Business Quant data shows WHWK's Shares Outstanding (Weighted Average) at $69.2 million in Q1 2026, $20.1 million in Q4 2025, and $59.4 million in Q3 2025.